Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by newdaydawningon Oct 25, 2019 5:41pm
152 Views
Post# 30271476

Today was relationship building with subject matter experts

Today was relationship building with subject matter expertsThe most important outcome of today's event are the new and hopefully enduring relationships that are formed. The key targets are the subject matter experts and key opinion leaders, foremost in  the investment community, and secondarily with media.

There are no shortage of bio-health technology advisors and analysts. Although I highly doubt those with the banks, insurance and pension funds would have an interest in TLT at this stage. Instead, Theralase must hone its pitch to the smaller independents.

Should TLT ever achieve a billion dollar valuation, I would expect the big institutions would start paying attention.


Bullboard Posts